BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang Y, Diao N, Lee CK, Chu HW, Bai L, Li L. Neutrophils Deficient in Innate Suppressor IRAK-M Enhances Anti-tumor Immune Responses. Mol Ther 2020;28:89-99. [PMID: 31607540 DOI: 10.1016/j.ymthe.2019.09.019] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Li Y, Tang M, Zhang FJ, Huang Y, Zhang J, Li J, Wang Y, Yang J, Zhu S. Screening of ulcerative colitis biomarkers and potential pathways based on weighted gene co-expression network, machine learning and ceRNA hypothesis. Hereditas 2022;159:42. [PMID: 36419192 DOI: 10.1186/s41065-022-00259-4] [Reference Citation Analysis]
2 Yao T, Xiao H, Wang H, Xu X. Recent Advances in PROTACs for Drug Targeted Protein Research. IJMS 2022;23:10328. [DOI: 10.3390/ijms231810328] [Reference Citation Analysis]
3 Que H, Fu Q, Lan T, Tian X, Wei X. Tumor-associated neutrophils and neutrophil-targeted cancer therapies. Biochim Biophys Acta Rev Cancer 2022;:188762. [PMID: 35853517 DOI: 10.1016/j.bbcan.2022.188762] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
4 He M, Cao C, Ni Z, Liu Y, Song P, Hao S, He Y, Sun X, Rao Y. PROTACs: great opportunities for academia and industry (an update from 2020 to 2021). Signal Transduct Target Ther 2022;7:181. [PMID: 35680848 DOI: 10.1038/s41392-022-00999-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
5 Wang Z, Huang W, Zhou K, Ren X, Ding K. Targeting the Non-Catalytic Functions: a New Paradigm for Kinase Drug Discovery? J Med Chem 2022. [PMID: 35000385 DOI: 10.1021/acs.jmedchem.1c01978] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
6 Bennett J, Starczynowski DT. IRAK1 and IRAK4 as emerging therapeutic targets in hematologic malignancies. Curr Opin Hematol 2022;29:8-19. [PMID: 34743084 DOI: 10.1097/MOH.0000000000000693] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
7 Wang C, Zhang Y, Wu Y, Xing D. Developments of CRBN-based PROTACs as potential therapeutic agents. Eur J Med Chem 2021;225:113749. [PMID: 34411892 DOI: 10.1016/j.ejmech.2021.113749] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 16.0] [Reference Citation Analysis]
8 Wang C, Zhang Y, Xing D, Zhang R. PROTACs technology for targeting non-oncoproteins: Advances and perspectives. Bioorg Chem 2021;114:105109. [PMID: 34175722 DOI: 10.1016/j.bioorg.2021.105109] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
9 Pradhan K, Geng S, Zhang Y, Lin RC, Li L. TRAM-Related TLR4 Pathway Antagonized by IRAK-M Mediates the Expression of Adhesion/Coactivating Molecules on Low-Grade Inflammatory Monocytes. J Immunol 2021:ji2000978. [PMID: 34031144 DOI: 10.4049/jimmunol.2000978] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
10 Su H, Cai T, Zhang S, Yan X, Zhou L, He Z, Xue P, Li J, Zheng M, Yang X, Feng B. Identification of hub genes associated with neutrophils infiltration in colorectal cancer. J Cell Mol Med 2021;25:3371-80. [PMID: 33666342 DOI: 10.1111/jcmm.16414] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
11 Degorce SL, Tavana O, Banks E, Crafter C, Gingipalli L, Kouvchinov D, Mao Y, Pachl F, Solanki A, Valge-Archer V, Yang B, Edmondson SD. Discovery of Proteolysis-Targeting Chimera Molecules that Selectively Degrade the IRAK3 Pseudokinase. J Med Chem 2020;63:10460-73. [PMID: 32803978 DOI: 10.1021/acs.jmedchem.0c01125] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
12 Liu M, Sun Q, Wei F, Ren X. Comprehensive insights into the effects and regulatory mechanisms of immune cells expressing programmed death-1/programmed death ligand 1 in solid tumors. Cancer Biol Med 2020;17:626-39. [PMID: 32944395 DOI: 10.20892/j.issn.2095-3941.2020.0112] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]